Home › Acute Myeloid Leukemia › New Jersey › Newark
Acute Myeloid Leukemia clinical trials in Newark, NJ
12 studies for Acute Myeloid Leukemia are looking for participants at sites in and around Newark (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Cooperman Barnabas Medical Center, Livingston · 9 mi away
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Cooperman Barnabas Medical Center, Livingston · 9 mi away
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
- Morristown Medical Center, Morristown · 17 mi away
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RecruitingPhase 2
- Cooperman Barnabas Medical Center, Livingston · 9 mi away
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Cooperman Barnabas Medical Center, Livingston · 9 mi away
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RecruitingPhase 2
- Cooperman Barnabas Medical Center, Livingston · 9 mi away
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
RecruitingPhase 3
- Clinical Trial Site, Morristown · 17 mi away
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RecruitingPhase 3
- Newark Beth Israel Medical Center, Newark
- Morristown Medical Center, Morristown · 17 mi away
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RecruitingPhase 1/2
- Atlantic Health, Morristown · 17 mi away
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RecruitingPhase 1/2
- Morristown Medical Center, Morristown · 17 mi away
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
RecruitingPhase 2/3
- Atlantic Health, Morristown · 17 mi away
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
RecruitingPhase 1/2
- Atlantic Health, Morristown · 17 mi away
About Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is a cancer of the white blood cells. AML usually gets worse quickly if it is not treated. Read more.
More about Acute Myeloid Leukemia on MedlinePlus
Acute Myeloid Leukemia trials in other cities
- Houston, TX88 studies
- New York City, NY51 studies
- Boston, MA44 studies
- Baldwin Park, CA41 studies
- Seattle, WA40 studies
- Durham, NC34 studies
- Columbus, OH34 studies
- Philadelphia, PA33 studies
- Atlanta, GA30 studies
- Tampa, FL30 studies
- Chicago, IL27 studies
- Los Angeles, CA25 studies
Other studies in Newark
- Breast Cancer17 studies
- Spinal Cord Injuries14 studies
- Metastatic Cancer10 studies
- Non-Small Cell Lung Cancer10 studies
- Heart Failure9 studies
- Pancreatic Cancer8 studies
- Melanoma8 studies
- Cardiovascular Disease8 studies
- Cancer (all types)7 studies
- Stroke7 studies
- Chronic Lymphocytic Leukemia7 studies
- Ovarian Cancer6 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.